IMMUNIC INC (IMUX) Stock Analyst Ratings
NASDAQ:IMUX - Nasdaq - US4525EP1011 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to IMUX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.43. This target is 957.48% above the current price.
IMUX was analyzed by 12 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IMUX.
In the previous month the buy percentage consensus was at a similar level.
IMUX was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-07 | EF Hutton | Maintains | Buy -> Buy |
| 2024-10-22 | EF Hutton | Maintains | Buy -> Buy |
| 2024-09-18 | EF Hutton | Maintains | Buy -> Buy |
| 2024-09-16 | EF Hutton | Initiate | Buy |
| 2024-08-27 | B. Riley Securities | Initiate | Buy |
| 2024-07-16 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-05 | Brookline Capital | Initiate | Buy |
| 2023-10-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-27 | Wedbush | Reiterate | Outperform -> Outperform |
| 2022-10-21 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-08-08 | Aegis Capital | Maintains | Buy |
| 2022-06-03 | SVB Leerink | Maintains | Outperform |
| 2022-05-18 | Piper Sandler | Maintains | Overweight |
| 2021-09-07 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-15 | Aegis Capital | Initiate | Buy |
| 2021-03-24 | JMP Securities | Initiate | Market Outperform |